SPAG16

Across TCGA pan-cancer cohorts, SPAG16 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPAG16 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SPAG16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPAG16 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, ESCA, and UCEC are the cancer types where SPAG16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
ESCA	OS	Median	II,III,IV	0.374	0.713	.005	18	view →
UCEC	DFS	Median	All	0.943	0.622	.013	8	view →
BLCA	OS	Median	III,IV	0.069	0.582	<.001	6	view →
LUAD	DFS	Median	II,III,IV	0.089	0.656	<.001	6	view →
LIHC	OS	Median	All	0.289	0.690	.043	6	view →
LUSC	OS	Median	III,IV	0.229	0.575	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPAG16–OV (DFS)

Open the OV breakdown →